Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

Brings substantial industry expertise and strategic focus for sustained company development.

Copenhagen, Denmark, July 15 , 2021 – Antag Therapeutics ApS, a privately-held biotechnology company focused on the development of novel treatments for dietary-related diseases with obesity as its prime focus, announced today the appointment of Dr. Christine Fischette to its Board of Directors.

Dr. Fischette has over 30 years of pharmaceutical experience, having held strategic and operational roles within research, drug development, commercialization and business development at Hoffman-LaRoche, Pfizer and Novartis. During Dr. Fischette’s time at Novartis, she identified, negotiated and executed multiple deals involving various deal structures, including asset acquisitions, with US, European, Japanese and Indian pharma companies. Prior to this, Dr. Fischette was Head of Pfizer’s US commercial arm for diabetes having worked across preclinical development, INDs, late-stage development/NDAs, medical marketing, business development. Under her leadership, she orchestrated Pfizer’s successful drug development program and market launch of the anti-diabetes drug Glucotrol XL [glipizide once daily] resulting in commercial peak sales of $350m.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH